Litcius/Paper detail

PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

Dun‐Chang Mo, Jianfeng Huang, Peng‐Hui Luo, Long Chen, Biao Zou, Han‐Lei Wang

2022European Archives of Oto-Rhino-Laryngology11 citationsDOI

Topics & Concepts

MedicineInternal medicineHazard ratioPembrolizumabChemotherapyHead and neck squamous-cell carcinomaOncologyAdverse effectOdds ratioGastroenterologyConfidence intervalHead and neck cancerRadiation therapyCancerImmunotherapyHead and Neck Cancer StudiesCancer Immunotherapy and BiomarkersNonmelanoma Skin Cancer Studies
PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma | Litcius